Literature DB >> 11880225

Biochemical and enzymatic characterization of a partially purified casein kinase-1 like activity from Trypanosoma cruzi.

Maritza Calabokis1, Liliana Kurz, Jeff Wilkesman, José Manuel Galán-Caridad, Carolina Möller, Mary Isabel Gonzatti, José Bubis.   

Abstract

Two protein kinase activities that use casein as a substrate, Q-I and Q-II, were identified in the epimastigote stage of Trypanosoma cruzi upon chromatography on Q-Sepharose. Q-I was purified further through concanavalin A-sepharose (Q-I*) to remove any trace of the contaminating protease cruzipain. The optimal activity for Q-I* was obtained at pH 8.0, 25 degreesC, 5 mM MgCl(2) and 75 mM NaCl. The size and pI of Q-I* were determined to be 33-36 kDa and 9.6, respectively. When two selective peptide substrates for casein kinases (CKs) (P1: RRKDLHDDEEDEAMSITA for CK1 and P2: RRRADDSDDDDD for CK2) were used, Q-I* was shown to specifically phosphorylate P1. Kinetic studies showed that Q-I* has a K(m) of 5.3 +/- 0.34 mg/ml for casein, 157.6 +/- 5.3 microM for P1 and 35.9 +/- 3.9 microM for ATP. The enzyme was inhibited by N-(2-amino-ethyl)-5-chloroisoquinoline-8-sulfonamide (CKI-7) or 1-(5-chloroisoquinoline-8-sulfonyl) (CKI-8), two inactivators of mammalian CKs. CKI-7 behaved as a competitive inhibitor with respect to ATP, with a K(I) of 75-100 microM. Treatment with high concentrations of polylysine or heparin also resulted in a significant inhibition of Q-I*. Two well-known activators of mammalian CKs, spermine and spermidine, were also tested. Spermine and spermidine activated Q-I* in a dose-dependent manner. Based on the following characteristics: (1) the ionic strength required for elution from anion-exchange resins; (2) its molecular size and monomeric structure; (3) pI; (4) high level of specificity for P1; (5) inactivation by CKI-7 and CKI-8; and (6) insensitivity to GTP and low concentrations of heparin, we conclude that Q-I* belongs to the CK1 family of protein kinases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880225     DOI: 10.1016/s1383-5769(01)00104-0

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  4 in total

1.  Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection.

Authors:  Najma Rachidi; Jean François Taly; Emilie Durieu; Olivier Leclercq; Nathalie Aulner; Eric Prina; Pascale Pescher; Cedric Notredame; Laurent Meijer; Gerald F Späth
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

2.  Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling.

Authors:  Jianghuai Liu; Lucas P Carvalho; Sabyasachi Bhattacharya; Christopher J Carbone; K G Suresh Kumar; N Adrian Leu; Peter M Yau; Robert G K Donald; Mitchell J Weiss; Darren P Baker; K John McLaughlin; Phillip Scott; Serge Y Fuchs
Journal:  Mol Cell Biol       Date:  2009-10-05       Impact factor: 4.272

Review 3.  Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates.

Authors:  Brad A Haubrich; David C Swinney
Journal:  Curr Drug Discov Technol       Date:  2016

4.  CK2 Secreted by Leishmania braziliensis Mediates Macrophage Association Invasion: A Comparative Study between Virulent and Avirulent Promastigotes.

Authors:  Ana Madeira Brito Zylbersztejn; Carlos Gustavo Vieira de Morais; Ana Karina Castro Lima; Joyce Eliza de Oliveira Souza; Angela Hampshire Lopes; Sílvia Amaral Gonçalves Da-Silva; Mário Alberto Cardoso Silva-Neto; Patrícia Maria Lourenço Dutra
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.